A detailed history of Cape Investment Advisory, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Cape Investment Advisory, Inc. holds 998 shares of GILD stock, worth $88,113. This represents 0.03% of its overall portfolio holdings.

Number of Shares
998
Previous 795 25.53%
Holding current value
$88,113
Previous $58.2 Million 17.6%
% of portfolio
0.03%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$63.15 - $72.88 $12,819 - $14,794
203 Added 25.53%
998 $68.5 Million
Q1 2024

Jun 21, 2024

SELL
$71.58 - $87.29 $14,244 - $17,370
-199 Reduced 20.02%
795 $58.2 Million
Q4 2023

Feb 12, 2024

BUY
$73.27 - $83.09 $7,400 - $8,392
101 Added 11.31%
994 $80.5 Million
Q2 2023

Oct 12, 2023

BUY
$76.01 - $86.7 $76 - $86
1 Added 0.11%
893 $68.8 Million
Q1 2023

Oct 12, 2023

BUY
$77.31 - $88.08 $68,960 - $78,567
892 New
892 $74 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $111B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Cape Investment Advisory, Inc. Portfolio

Follow Cape Investment Advisory, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cape Investment Advisory, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cape Investment Advisory, Inc. with notifications on news.